Abstract
One hundred and ninety-one adults with acute myelogenous leukaemia were treated with combination chemotherapy consisting of daunorubicin and cytosine arabinoside (Barts III). Sixty-three patients achieved remission and were admitted to one of 3 trials of active immunotherapy: immunotherapy alone, immunotherapy and maintenance chemotherapy or neither of these. All patients had weekly clinical and blood examination and monthly marrow examination. Reinduction chemotherapy was given as soon as relapse was diagnosed in the marrow. The most striking observation was that immunotherapy was associated with easy and repeated reinduction of remission and marked prolongation of survival after first relapse when compared with immunotherapy plus chemotherapy. The possible reasons for this and the value of immunotherapy are discussed in relation to the third trial still in progress which includes 2 maintenance arms, immunotherapy alone and surveillance only.
Full text
PDF
Selected References
These references are in PubMed. This may not be the complete list of references from this article.
- Bailey C. C., Geary C. G., Israëls M. C., Whittaker J. A., Brown M. J., Weatherall D. J. Cytosine arabinoside in the treatment of acute myeloblastic leukaemia. Lancet. 1971 Jun 19;1(7712):1268–1271. doi: 10.1016/s0140-6736(71)91781-8. [DOI] [PubMed] [Google Scholar]
- Crowther D., Powles R. L., Bateman C. J., Beard M. E., Gauci C. L., Wrigley P. F., Malpas J. S., Fairley G. H., Scott R. B. Management of adult acute myelogenous leukaemia. Br Med J. 1973 Jan 20;1(5846):131–137. doi: 10.1136/bmj.1.5846.131. [DOI] [PMC free article] [PubMed] [Google Scholar]
- Freeman C. B., Harris R., Geary C. G., Leyland M. J., MaCiver J. E., Delamore I. W. Active immunotherapy used alone for maintenance of patients with acute myeloid leukaemia. Br Med J. 1973 Dec 8;4(5892):571–573. doi: 10.1136/bmj.4.5892.571. [DOI] [PMC free article] [PubMed] [Google Scholar]
- Gale R. P., Cline M. J. High remission-induction rate in acute myeloid leukaemia. Lancet. 1977 Mar 5;1(8010):497–499. doi: 10.1016/s0140-6736(77)91366-6. [DOI] [PubMed] [Google Scholar]
- Powles R. L., Crowther D., Bateman C. J., Beard M. E., McElwain T. J., Russell J., Lister T. A., Whitehouse J. M., Wrigley P. F., Pike M. Immunotherapy for acute myelogenous leukaemia. Br J Cancer. 1973 Nov;28(5):365–376. doi: 10.1038/bjc.1973.162. [DOI] [PMC free article] [PubMed] [Google Scholar]
- Powles R. L., Russell J., Lister T. A., Oliver T., Whitehouse J. M., Malpas J., Chapuis B., Crowther D., Alexander P. Immunotherapy for acute myelogenous leukaemia: a controlled clinical study 2 1/2 years after entry of the last patient. Br J Cancer. 1977 Mar;35(3):265–272. doi: 10.1038/bjc.1977.38. [DOI] [PMC free article] [PubMed] [Google Scholar]
- Powles R. Immunotherapy for acute myelogenous leukaemia. Br J Cancer Suppl. 1973 Aug;1:262–265. [PMC free article] [PubMed] [Google Scholar]
- Whittaker J. A., Slater A. J. The immunotherapy of acute myelogenous leukaemia using intravenous BCG. Br J Haematol. 1977 Feb;35(2):263–273. doi: 10.1111/j.1365-2141.1977.tb00583.x. [DOI] [PubMed] [Google Scholar]
- Wiernik P. H., Serpick A. A. Factors effecting remission and survival in adult acute nonlymphocytic leukemia (ANLL). Medicine (Baltimore) 1970 Nov;49(6):505–513. doi: 10.1097/00005792-197011000-00004. [DOI] [PubMed] [Google Scholar]